कृपया अन्य खोज का प्रयास करें
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company’s lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer’s Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. The company was founded in 2017 and is headquartered in Bethesda, Maryland.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Khalid Islam | 68 | 2017 | Founder & Chairman |
Matthias Alder | 58 | 2021 | President, CEO & Director |
Jeffrey Lucero Riley | 61 | 2019 | Independent Director |
Luca Benatti | 63 | 2021 | Chairman of the Scientific Advisory Board |
Samuel E. Broder | 79 | - | Member of Scientific Advisory Board |
Gwen A. Melincoff | 72 | 2021 | Independent Director |
Eric I. Richman | 63 | 2020 | Director |
Dov A. Goldstein | 57 | 2021 | Independent Director |
Hans Peter Hasler | 68 | 2021 | Independent Director |
Claude Nicaise | 71 | 2021 | Independent Director |
Michel Vellard | - | 2018 | Member of Scientific Advisory Board |
Lorenzo Leoni | 59 | 2021 | Member of Scientific Advisory Board |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है